ClinicalTrials.gg

Glomerulonephritis, Membranous clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 146 studies for Glomerulonephritis, Membranous across more than 10 countries. 60 are recruiting or about to start. 111 of them are mainly about Glomerulonephritis, Membranous (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16.

Status

Completed
45
Recruiting
41
Not yet recruiting
18
Status unknown
17
Terminated
11
Active, not recruiting
10

Phase

Phase 2
45
Phase 3
27
Phase 1
14
Phase 4
12
Early Phase 1
5

Where

China
60
United States
35
France
18
Italy
15
United Kingdom
12
Spain
9

Who develops what

Add Glomerulonephritis, Membranous to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 11 programs from 10 companies, 10 with this as their studies’ main aim; 3 with a live phase 3 study; 5 primary completions in the next 12 months. Compare AstraZeneca, Amgen and CSPC Pharmaceutical Group here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
TacrolimusRecent, repeated
Evidence
  • NCT07851220 · Amgen · Phase 3 · live · comparator · “Tacrolimus” · registered Sep 2026
  • NCT07204275 · Vertex Pharmaceuticals Incorporated · Phase 3 · live · comparator · “Tacrolimus” · registered Sep 2025
  • NCT06962800 · Biogen · Phase 3 · live · background · “Tacrolimus” · registered Apr 2025
  • NCT05707377 · BeOne Medicines · Phase 3 · live · comparator · “Tacrolimus” · registered Jan 2023
  • NCT04629248 · Hoffmann-La Roche · Phase 3 · live · comparator · “Tacrolimus” · registered Oct 2020
Astellas Pharma Inc62% of its industry studiesUS: off-patent, 17 generics marketedEU: off-patent, 1 generic authorized44 studies
CyclosporineRecent, repeated
Evidence
  • NCT07830433 · BioRay Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Cyclosporine” · registered Sep 2026
  • NCT06642909 · BioRay Pharmaceutical Co., Ltd. · Phase 2 · live · comparator · “cyclosporine” · registered Oct 2024
  • NCT06470191 · Shanghai Jiaolian Drug Research and Development Co., Ltd · Phase 3 · live · comparator · “Cyclosporin Capsules” · registered Jun 2024
  • NCT05862233 · Beijing Mabworks Biotech Co., Ltd. · Phase 3 · live · comparator · “Cyclosporine” · registered May 2023
  • NCT05398653 · Beijing Mabworks Biotech Co., Ltd. · Phase 2 · comparator · “Cyclosporine” · registered May 2022
Novartis23% of its industry studiesUS: off-patent, 15 generics marketedEU: Santen Pharmaceutical Co., Ltd. (EMA 2015) + 1 other35 studies

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
povetacicept☆ Track1 live phase-3 study: NCT07204275Vertex Pharmaceuticals Incorporated
zuberitamab☆ Track1 live phase-3 study: NCT07830433BioRay Pharmaceutical Co., Ltd.
inebilizumabApproved: US 2020 · EU 2022☆ Track1 live phase-3 study: NCT07851220Amgen

The 3 in phase 3 with the nearest primary completion, of 11 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (5)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 31 Mar 2027 est.zuberitamab · BioRay Pharmaceutical Co., Ltd. · Phase 2 main aimvs CyclosporineNCT06642909 A Phase II Study of Zuberitamab Injection in Patients With Primary Membranous Nephropathy — primary endpoint: The proportion of subjects who achieved overall response (OR) in the urinary protein/creatinine ratio (UPCR) at week 76 · 135 enrolled
  • 1 Apr 2027 est.CPO-107 · CSPC Pharmaceutical Group Limited · Phase 2 main aimNCT07029139 A Study to Learn More About the Effects and Safety of JMT601 in Adults With Primary Membranous Nephropathy — primary endpoint: Incidence of adverse events in Part 1 · 156 enrolled
  • 2 Jul 2027 est.ALXN1920 · AstraZeneca · Phase 2 main aimNCT07157787 Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN) — primary endpoint: Change From Baseline in Proteinuria Based on 24-hour UPCR at Week 26 · 30 enrolled

2 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Glomerulonephritis, Membranous studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Calcineurin inhibitors 2 open · Factor Xa inhibitors 1 open

Coming up

18studies finish main data collection within a year2 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 41 Glomerulonephritis, Membranous studies recruiting now, 14 (34%) set no upper age limit and 14 (34%) stop at 75 or younger. 8 (20%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 2 (5%) take healthy volunteers.

Recruiting studies that take each age, of 41
AgeWomenMen
108 (20%)8 (20%)
1841 (100%)41 (100%)
3040 (98%)40 (98%)
4040 (98%)40 (98%)
5040 (98%)40 (98%)
6540 (98%)40 (98%)
7539 (95%)39 (95%)
8518 (44%)18 (44%)

Across all 146 studies, recruiting or not: 36% stop at 75 or younger and 6% at 65; 13% take children; 1% are for women only and 0% for men only; 8% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 146. Browse all 146 → or search them.